Abstract
Get full access to this article
View all access options for this article.
References
1.Fast track, breakthrough therapy, accelerated approval and priority review: Expediting availability of new drugs for patients with serious conditions . US Food and Drug Administration: For Consumers. June 26, 2013. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm. Accessed August 9, 2013.
2.Frequently asked questions: Breakthrough therapies. US Food and Drug Administration. July 31, 2013. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm341027.htm. Accessed August 9, 2013 .
3.
Sawyers CL
Haber DA
Horning SJ
Ivy SP
Selig WKD
. Developing standards for breakthrough therapy designation. Conference on Clinical Cancer Research. November 2012. http://www.focr.org/sites/default/files/CCCR12Breakthrough.pdf. Accessed August 9, 2013 .
4.Guidance for industry: Expedited programs for serious conditions – drugs and biologics [draft guidance]. US Food and Drug Administration. June 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf. August 9, 2013 .
5.Food and Drug Administration Safety and Innovation Act (FDASIA). July 12, 2013. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/default.htm. Accessed August 9, 2013 .
6.These 2 companies are the biggest winners of the FDA's breakthrough designation. The Motley Fool. August 31, 2013. Accessed September 3, 2013.
7.Catalyst Pharmaceutical partners receive breakthrough therapy designation from FDA for Firdapse for the treatment of LEMS. Goblenewswire.com. August 27, 2013. Accessed August 27, 2013.
8.Ariad Pharma denied FDA's coveted “breakthrough” stamp for lung cancer drug. FierceBiotech. August 9, 2013. http://www.fiercebiotech.com/story/ariad-pharma-denied-fdas-coveted-breakthrough-stamp-lung-cancer-drug/2013-08-09. Accessed August 9, 2013 .
9.What makes a breakthrough cancer drug in the eyes of the FDA. Online Wall Street Journal. June 3, 2013. http://online.wsj.com/article/BT-CO-20130603-709091.html. Accessed August 9, 2013 .
10.
Moore TJ
Furberg CD
. The safety risks of innovation: The FDA's expedited drug development pathway . JAMA . 2013 ;308 (9 ):869 –870 .
11.
Silverman E
Is the FDA sacrificing safety for speed? Pharmalot. September 5, 2013 . http://www.pharmalive.com/fda-sacrificing-safety-speed. Accessed September 16, 2013 .
12.
Clarke T. U.S
. drugmakers cheer “speed lane” for breakthrough therapies . Reuters. July 24, 2013 . http://www.reuters.com/article/2013/07/24/usa-fda-drug-therapies-idUSL1N0FU1XZ20130724. Accessed September 16, 2013 .
13.
Carroll J.
Breakthrough drug category demands more communication . Managed Care. August 17-18, 2013 . http://www.managedcaremag.com/archives/2013/8/breakthrough-drug-category-demands-more-communication. Accessed September 16, 2013 .
14.
Woodcock J.
“Breakthrough” designation… another powerful tool in FDA's toolbox for expediting the development and review of promising new drugs for serious conditions . FDA Voice . June 25, 2013 . http://blogs.fda.gov/fdavoice/index.php/2013/06/breakthrough-designation-another-powerful-tool-in-fdas-toolbox-for-expediting-the-development-and-review-of-promising-new-drugs-for-serious-conditions/. Accessed August 9, 2013 .